Arcutis Biotherapeutics/$ARQT
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Arcutis Biotherapeutics
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
Ticker
$ARQT
Sector
Primary listing
Employees
342
Headquarters
Website
ARQT Metrics
BasicAdvanced
$3B
-
-$0.35
2.06
-
Price and volume
Market cap
$3B
Beta
2.06
52-week high
$27.08
52-week low
$8.90
Average daily volume
2.6M
Financial strength
Current ratio
3.5
Quick ratio
3.069
Long term debt to equity
71.343
Total debt to equity
71.976
Interest coverage (TTM)
-2.61%
Profitability
EBITDA (TTM)
-33.189
Gross margin (TTM)
89.96%
Net profit margin (TTM)
-13.94%
Operating margin (TTM)
-12.03%
Effective tax rate (TTM)
-2.36%
Revenue per employee (TTM)
$930,000
Management effectiveness
Return on assets (TTM)
-5.91%
Return on equity (TTM)
-28.17%
Valuation
Price to revenue (TTM)
9.634
Price to book
18.44
Price to tangible book (TTM)
20.42
Price to free cash flow (TTM)
-63.486
Free cash flow yield (TTM)
-1.58%
Free cash flow per share (TTM)
-0.382
Growth
Revenue change (TTM)
129.21%
Earnings per share change (TTM)
-79.75%
3-year revenue growth (CAGR)
659.74%
3-year earnings per share growth (CAGR)
-61.06%
What the Analysts think about ARQT
Analyst ratings (Buy, Hold, Sell) for Arcutis Biotherapeutics stock.
Bulls say / Bears say
Arcutis delivered $99.2 million in Q3 2025 net ZORYVE sales, a 122% year-over-year and 22% sequential increase, reflecting robust commercial momentum. (Investing.com)
Following early October FDA approval, Arcutis plans to launch ZORYVE cream 0.05% for atopic dermatitis in children ages 2–5 by month-end, expanding its addressable pediatric market. (Investing.com)
Management provided initial guidance for 2026 net product sales of $455 million–$470 million, signaling confidence in sustained ZORYVE growth and supporting a bullish outlook. (Investing.com)
Despite ZORYVE’s strong top-line growth, Arcutis reported a net loss of $0.13 per share in Q2 2025, underscoring ongoing profitability challenges. (Investor’s Business Daily)
Arcutis’ high operating cost base remains a headwind, with Q1 2025 SG&A expenses of $64.0 million and R&D spending of $17.5 million consuming revenue and resulting in a $25.1 million net loss. (GlobeNewswire)
The company’s near-term revenue is concentrated in its ZORYVE franchise while its next pipeline candidate, ARQ-234, is only entering Phase 1, indicating limited diversification and longer timelines for new product launches. (Arcutis Press Release)
Data summarised monthly by Lightyear AI. Last updated on 8 Nov 2025.
ARQT Financial Performance
Revenues and expenses
ARQT Earnings Performance
Company profitability
ARQT News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Arcutis Biotherapeutics stock?
Arcutis Biotherapeutics (ARQT) has a market cap of $3B as of November 11, 2025.
What is the P/E ratio for Arcutis Biotherapeutics stock?
The price to earnings (P/E) ratio for Arcutis Biotherapeutics (ARQT) stock is 0 as of November 11, 2025.
Does Arcutis Biotherapeutics stock pay dividends?
No, Arcutis Biotherapeutics (ARQT) stock does not pay dividends to its shareholders as of November 11, 2025.
When is the next Arcutis Biotherapeutics dividend payment date?
Arcutis Biotherapeutics (ARQT) stock does not pay dividends to its shareholders.
What is the beta indicator for Arcutis Biotherapeutics?
Arcutis Biotherapeutics (ARQT) has a beta rating of 2.06. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.